SEC Tracker
Get the app

Supernus Pharmaceuticals SUPN

Supernus Pharmaceuticals delisted after merger

Nasdaq delisting decision, Item 3.01 Listing standards notice

Form
8-K
Filed
Importance
Major
  1. Merger completed on November 2, 2026
  2. Nasdaq suspended trading of Supernus Common Stock
  3. Form 25 filed to delist from Nasdaq
  4. Form 15 requested to deregister under Section 12(g)

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Supernus Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The filing includes a notice of delisting from Nasdaq and requests for the suspension of trading and deregistration of its common stock.
  2. The company also plans to file a Form 15 to suspend reporting obligations under the Exchange Act.
  3. The company's stock will no longer be listed on any national securities exchange following the merger.

3 of 7 claims matched the filing text.

Not found in the filing text

  • The filing confirms the company's intent to cease reporting obligations under the Exchange Act.
  • For the quarter ended September 30, 2026, Supernus Pharmaceuticals, Inc. reported revenue of $226.8 million.
  • The company had a net income of $20.9 million, with a gross margin of 88.1%.
  • These financial results were included in the 10-Q filing for the quarter ended September 30, 2026.

From the filing

Item 3.01

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.1

In connection with the consummation of the Merger on November 2, 2026, Supernus Pharmaceuticals, Inc. (the "Company") notified Nasdaq of the completion of the Merger and requested that Nasdaq (i) suspend trading of the Supernus Common Stock, effective prior to the opening of trading on November 2, 2026, and (ii) file with the SEC a Notification of Removal from Listing and/or Registration on Form 25 to effect the delisting of the Supernus Common Stock from Nasdaq and the deregistration of the Supernus Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended1 (the " Exchange Act "). Following the effectiveness of such Form 25, the Company intends to file with the SEC a certification on Form 15 requesting the deregistration of the Supernus Common Stock under Section 12(g) of the Exchange Act and the suspension of the Company's reporting obligations under Sections 13 and 15(d) of the Exchange Act2. As a result of the Merger, the Supernus Common Stock will no longer be listed on any national securities exchange3.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Supernus Pharmaceuticals, Inc.

Date: November 2, 2026

By:

/s/ Timothy C. Dec

Timothy C. Dec

Senior Vice President and Chief Financial Officer

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Sarepta Therapeutics SRPT public float $1.7B, Jun 30, 2025
  2. Amicus Therapeutics FOLD public float $1.7B, Jun 30, 2025
  3. Ocular Therapeutix OCUL public float $1.6B, Jun 30, 2025
  4. Ligand Pharmaceuticals LGND public float $1.6B, Jun 30, 2025
  5. Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025